NasdaqGS - Nasdaq Real Time Price USD

Lifecore Biomedical, Inc. (LFCR)

Compare
7.07 +0.13 (+1.87%)
At close: December 19 at 4:00:03 PM EST
7.07 0.00 (0.00%)
After hours: December 19 at 4:02:15 PM EST
Loading Chart for LFCR
DELL
  • Previous Close 6.94
  • Open 7.19
  • Bid 7.04 x 100
  • Ask 7.12 x 100
  • Day's Range 6.87 - 7.19
  • 52 Week Range 3.68 - 8.90
  • Volume 204,548
  • Avg. Volume 169,226
  • Market Cap (intraday) 260.367M
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) 54.38
  • EPS (TTM) 0.13
  • Earnings Date Jan 2, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.00

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

www.lifecore.com

524

Full Time Employees

May 26

Fiscal Year Ends

Recent News: LFCR

View More

Performance Overview: LFCR

Trailing total returns as of 12/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LFCR
14.22%
S&P 500
23.00%

1-Year Return

LFCR
19.63%
S&P 500
23.76%

3-Year Return

LFCR
34.05%
S&P 500
26.98%

5-Year Return

LFCR
40.54%
S&P 500
83.86%

Compare To: LFCR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LFCR

View More

Valuation Measures

Annual
As of 12/19/2024
  • Market Cap

    260.37M

  • Enterprise Value

    391.71M

  • Trailing P/E

    54.38

  • Forward P/E

    8.67

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.02

  • Price/Book (mrq)

    15.35

  • Enterprise Value/Revenue

    3.05

  • Enterprise Value/EBITDA

    11.53

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.09%

  • Return on Assets (ttm)

    -2.25%

  • Return on Equity (ttm)

    17.29%

  • Revenue (ttm)

    128.44M

  • Net Income Avi to Common (ttm)

    5.71M

  • Diluted EPS (ttm)

    0.13

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.52M

  • Total Debt/Equity (mrq)

    346.46%

  • Levered Free Cash Flow (ttm)

    -10.53M

Research Analysis: LFCR

View More

Company Insights: LFCR

Research Reports: LFCR

View More

People Also Watch